M8W.F MediWound Ltd

Healthcare Biotechnology Frankfurt Exchange
11.50 EUR
Close of Nov 13, 2026
10.30 17.00
Market cap
EUR 165M
P/E
-
P/B
5.50x
ROE
-58.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is M8W.F undervalued?

Graham number

The Graham number of MediWound Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MediWound Ltd fundamental analysis

No fundamental analysis for MediWound Ltd yet.

MediWound Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MediWound Ltd

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bio…

Full company profile